Pfizer and BioNTech's Coronavirus Vaccine Candidate Produces Antibodies in People Up to 85 Years Old
If a vaccine does its job, it will produce a strong immune response in the patients inoculated with it -- driving the body to make antibodies to the illness in question. But different groups of people may react in different ways to any given vaccine.
In the case of COVID-19, it's particularly important that a vaccine be capable of generating antibodies well in older people, since they tend to suffer worse outcomes more often when infected with the novel coronavirus.
Thursday brought a bit of positive news on that front: Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) revealed that their leading coronavirus vaccine candidate, BNT162b2, appears to be generating antibodies in its study subjects at higher concentrations than those found in patients who have recovered from COVID-19.
Source Fool.com
